Detail akcie Regencell Rg online

Business Summary: Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2023, Regencell Bioscience Holdings Ltd revenues was not reported. Net loss decreased 21% to $5.9M. Lower net loss reflects Pharmaceuticals & Medical Research segment loss decrease of 18% to $6.3M, Hong Kong segment loss decrease of 18% to $6.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.58 to -$0.45.